Cingulate CINGW
NASDAQ CINGW
$0.01 +0.00 (+4.29%)
As of: Sep 9, 2026 · 11:16 AM EDT

Cingulate (CINGW) Liabilities and Shareholders Equity (2021 - 2026)

Cingulate's (CINGW) quarterly Liabilities and Shareholders Equity came in at $33.1 million in Q2 2026, up 119.37% quarter-over-quarter from $15.1 million in Q4 2025.

Analysis

Cingulate (CINGW) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Cingulate (CINGW) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $33.1 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $33.1 million; the trailing twelve-month figure through Jun 2026 stood at $58.7 million (up 43.37% YoY), and the FY2025 full-year result was $15.1 million, up 1.4% from the prior year.
  • Liabilities and Shareholders Equity rose to $33.1 million in Q2 2026 per CINGW's latest filing, from $15.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $33.1 million in Q2 2026 and bottomed at $3.5 million in Q4 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $11.9 million across 5 years, with a median of $11.9 million in 2022.
  • The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 69.39% in 2023, then soared 325.74% in 2024.
  • Over 5 years, Liabilities and Shareholders Equity stood at $11.4 million in 2022, then tumbled by 69.39% to $3.5 million in 2023, then jumped by 325.74% to $14.9 million in 2024, then climbed by 1.4% to $15.1 million in 2025, then soared by 119.37% to $33.1 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $33.1 million, $15.1 million, and $10.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 646.24 Bn 625.48 Bn 17.26 Bn 201.06 Bn
2 AbbVie 441.52 Bn 434.96 Bn 12.70 Bn 135.12 Bn
3 Merck 365.75 Bn 358.60 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 266.61 Bn 258.92 Bn 11.24 Bn 122.03 Bn
5 Pfizer 159.09 Bn 147.39 Bn 10.94 Bn 201.13 Bn
6 Sanofi 52.43 Bn 45.05 Bn 10.79 Bn 150.01 Bn
7 Revolution Medicines 44.04 Bn 44.04 Bn - 4.32 Bn
8 Incyte 25.32 Bn 20.79 Bn 1.57 Bn 7.87 Bn
9 United Therapeutics 21.43 Bn 18.77 Bn 683.80 Mn 7.22 Bn
10 Cingulate 100,214.03 100,214.03 - 33.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 33.07 Mn
Dec 31, 2025 15.07 Mn
Sep 30, 2025 10.52 Mn
Mar 31, 2025 12.47 Mn
Dec 31, 2024 14.86 Mn
Sep 30, 2024 13.58 Mn
Jun 30, 2024 5.13 Mn
Mar 31, 2024 5.49 Mn
Dec 31, 2023 3.49 Mn
Sep 30, 2023 5.87 Mn
Jun 30, 2023 5.23 Mn
Mar 31, 2023 7.16 Mn
Dec 31, 2022 11.41 Mn
Sep 30, 2022 15.38 Mn
Jun 30, 2022 13.80 Mn
Mar 31, 2022 18.43 Mn
Dec 31, 2021 22.89 Mn